Free Trial

4D Molecular Therapeutics (FDMT) Competitors

4D Molecular Therapeutics logo
$4.10 -0.22 (-4.99%)
Closing price 07/3/2025 03:54 PM Eastern
Extended Trading
$4.22 +0.13 (+3.17%)
As of 07/3/2025 04:47 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

FDMT vs. SION, GYRE, PHAT, ANAB, IMTX, TRVI, NUVB, DAWN, GHRS, and STOK

Should you be buying 4D Molecular Therapeutics stock or one of its competitors? The main competitors of 4D Molecular Therapeutics include Sionna Therapeutics (SION), Gyre Therapeutics (GYRE), Phathom Pharmaceuticals (PHAT), AnaptysBio (ANAB), Immatics (IMTX), Trevi Therapeutics (TRVI), Nuvation Bio (NUVB), Day One Biopharmaceuticals (DAWN), GH Research (GHRS), and Stoke Therapeutics (STOK). These companies are all part of the "pharmaceutical products" industry.

4D Molecular Therapeutics vs. Its Competitors

Sionna Therapeutics (NASDAQ:SION) and 4D Molecular Therapeutics (NASDAQ:FDMT) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, dividends, profitability, valuation, analyst recommendations, institutional ownership and media sentiment.

Sionna Therapeutics currently has a consensus price target of $38.50, indicating a potential upside of 81.69%. 4D Molecular Therapeutics has a consensus price target of $29.56, indicating a potential upside of 621.75%. Given 4D Molecular Therapeutics' higher probable upside, analysts clearly believe 4D Molecular Therapeutics is more favorable than Sionna Therapeutics.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Sionna Therapeutics
0 Sell rating(s)
0 Hold rating(s)
3 Buy rating(s)
0 Strong Buy rating(s)
3.00
4D Molecular Therapeutics
1 Sell rating(s)
2 Hold rating(s)
7 Buy rating(s)
0 Strong Buy rating(s)
2.60

99.3% of 4D Molecular Therapeutics shares are owned by institutional investors. 3.9% of Sionna Therapeutics shares are owned by company insiders. Comparatively, 9.6% of 4D Molecular Therapeutics shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

In the previous week, 4D Molecular Therapeutics had 3 more articles in the media than Sionna Therapeutics. MarketBeat recorded 9 mentions for 4D Molecular Therapeutics and 6 mentions for Sionna Therapeutics. Sionna Therapeutics' average media sentiment score of 1.15 beat 4D Molecular Therapeutics' score of 0.07 indicating that Sionna Therapeutics is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Sionna Therapeutics
3 Very Positive mention(s)
0 Positive mention(s)
2 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
4D Molecular Therapeutics
0 Very Positive mention(s)
1 Positive mention(s)
7 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Neutral

Sionna Therapeutics has a net margin of 0.00% compared to 4D Molecular Therapeutics' net margin of -767,126.06%. Sionna Therapeutics' return on equity of 0.00% beat 4D Molecular Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Sionna TherapeuticsN/A N/A N/A
4D Molecular Therapeutics -767,126.06%-33.26%-30.68%

Sionna Therapeutics has higher earnings, but lower revenue than 4D Molecular Therapeutics.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Sionna TherapeuticsN/AN/A-$61.69MN/AN/A
4D Molecular Therapeutics$40K4,743.03-$160.87M-$3.18-1.29

Summary

Sionna Therapeutics and 4D Molecular Therapeutics tied by winning 6 of the 12 factors compared between the two stocks.

Get 4D Molecular Therapeutics News Delivered to You Automatically

Sign up to receive the latest news and ratings for FDMT and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding FDMT and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

FDMT vs. The Competition

Metric4D Molecular TherapeuticsMED IndustryMedical SectorNASDAQ Exchange
Market Cap$196.42M$2.43B$5.56B$9.05B
Dividend YieldN/A1.78%5.24%3.99%
P/E Ratio-1.299.0227.6520.23
Price / Sales4,743.03680.43419.56119.26
Price / CashN/A21.7726.2128.59
Price / Book0.374.558.035.65
Net Income-$160.87M$31.26M$3.18B$249.15M
7 Day Performance6.64%3.25%2.93%3.28%
1 Month Performance-5.86%3.46%1.72%3.95%
1 Year Performance-80.64%0.77%34.39%20.98%

4D Molecular Therapeutics Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
FDMT
4D Molecular Therapeutics
2.2791 of 5 stars
$4.10
-5.0%
$29.56
+621.7%
-80.6%$196.42M$40K-1.29120News Coverage
Analyst Forecast
SION
Sionna Therapeutics
N/A$17.35
+9.5%
$38.50
+121.9%
N/A$698.93MN/A0.0035Positive News
Insider Trade
GYRE
Gyre Therapeutics
0.0793 of 5 stars
$7.35
-0.9%
N/A-34.5%$695.68M$105.76M367.6840
PHAT
Phathom Pharmaceuticals
3.5903 of 5 stars
$9.59
-1.5%
$17.50
+82.5%
-14.9%$679.99M$55.25M-1.83110
ANAB
AnaptysBio
2.286 of 5 stars
$22.20
-1.2%
$42.38
+90.9%
-2.8%$660.18M$91.28M-4.58100News Coverage
Insider Trade
IMTX
Immatics
2.4202 of 5 stars
$5.38
-0.9%
$14.67
+172.6%
-52.0%$660.02M$168.65M-31.65260Positive News
TRVI
Trevi Therapeutics
3.2765 of 5 stars
$5.47
-2.7%
$20.29
+270.9%
+128.5%$659.19MN/A-12.1620News Coverage
Analyst Forecast
Analyst Revision
NUVB
Nuvation Bio
3.4398 of 5 stars
$1.96
+1.3%
$7.17
+266.6%
-31.2%$656.71M$7.87M-0.8360High Trading Volume
DAWN
Day One Biopharmaceuticals
1.7011 of 5 stars
$6.50
+0.5%
$30.57
+370.3%
-50.4%$655.82M$131.16M-9.1560Upcoming Earnings
GHRS
GH Research
1.5715 of 5 stars
$12.19
-2.0%
$32.00
+162.5%
+26.9%$647.23MN/A-15.4310News Coverage
Analyst Upgrade
STOK
Stoke Therapeutics
4.0255 of 5 stars
$11.35
-2.4%
$23.20
+104.4%
-12.5%$634.96M$190.91M14.37100News Coverage
Analyst Forecast

Related Companies and Tools


This page (NASDAQ:FDMT) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners